- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | XFRA NEW INSTRUMENTS AVAILABLE ON 01.09.2026 | 157 | Xetra Newsboard | The following instruments on XETRA do have their first trading 01.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 01.09.2026
Aktien
1 VGG863021256 SWVL Holdings Corp.
2... ► Artikel lesen | |
| 21.08. | Pharmala Biotech Holdings Inc: Pharmala gains U.S. patent, cancels APA-01 licence | 2 | Stockwatch | ||
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 21.08. | PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner | 507 | GlobeNewswire (Europe) | U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO)PharmAla has exercised... ► Artikel lesen | |
| 30.07. | Pharmala Biotech Holdings Inc: Pharmala Biotech loses $499,759 in fiscal Q3 | 1 | Stockwatch | ||
| 30.07. | PharmAla Biotech: PharmAla Issues Q3 Financial Statements and AGM Update | 211 | GlobeNewswire (Europe) | TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 21.07. | Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drug | 1 | FierceBiotech | ||
| 21.07. | Pharmala Biotech Holdings Inc: Pharmala licenses U.S. rights to ALA-002 to Jupiter | 1 | Stockwatch | ||
| 21.07. | PharmAla licenses ALA-002 drug to Jupiter for US market | 2 | Investing.com | ||
| 21.07. | PharmAla vergibt US-Lizenz für Wirkstoffkandidat ALA-002 an Jupiter | 1 | Investing.com Deutsch | ||
| 21.07. | PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 | 339 | GlobeNewswire (Europe) | TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 07.07. | Pharmala Biotech Holdings Inc: Pharmala completes ALA-002 GMP drug substance run | 1 | Stockwatch | ||
| 06.07. | PharmAla Biotech: PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset | 163 | GlobeNewswire (Europe) | TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo MDMA and... ► Artikel lesen | |
| 20.05. | Pharmala Biotech Holdings Inc: Pharmala signs U.S. ALA-002 licensing term sheet | 3 | Stockwatch | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 763 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | Pharmala Biotech Holdings Inc: Pharmala signs definitive agreement to form SPV Restora | 1 | Stockwatch | ||
| 13.05. | PharmAla forms joint venture to develop novel MDXX molecule | 1 | Investing.com | ||
| 13.05. | PharmAla gründet Joint Venture zur Entwicklung eines neuartigen MDXX-Moleküls | 2 | Investing.com Deutsch | ||
| 13.05. | PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 | 193 | GlobeNewswire (Europe) | TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ("PharmAla" or the "Company"), a leader in the research, development, and manufacturing of clinical-grade... ► Artikel lesen | |
| 27.04. | Pharmala Biotech Holdings Inc: Pharmala, Aluvaris sign LOI for special-purpose vehicle | 3 | Stockwatch |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| QIAGEN | 36,340 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | ||
| PARABILIS MEDICINES | 40,420 | 0,00 % | Parabilis Medicines, Inc. - 8-K, Current Report |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +17,91 % bei einem Aktienkurs von 0,156 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.